Last reviewed · How we verify

NCT04597827: META-DEM

Metacognition in Semantic Dementia: Comparison With Alzheimer's Disease

Completed Last updated 7 August 2023
What this trial tests

trial testing Metacognition tests in Semantic Dementia in 40 participants. Completed in 27 April 2022.

Timeline
16 October 2020
Primary endpoint
27 April 2022
27 April 2022

Quick facts

Lead sponsorUniversity Hospital, Grenoble
StatusCompleted
Study typeOBSERVATIONAL
Enrollment40
Start date16 October 2020
Primary completion27 April 2022
Estimated completion27 April 2022
Sites7 locations across France, Switzerland

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Grenoble

Who can join

Eligibility, any sex, with Semantic Dementia or Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims at exploring patients' ability to monitor their own memory performance depending on their primary deficit and the type of memory involved in the criterion task. The goal is to evaluate if semantic dementia (SD) and Alzheimer's disease (AD) differently affect patients' awareness of their memory abilities.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Semantic Dementia

Currently open trials in the same condition.

Other University Hospital, Grenoble trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04597827.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing